
Home / Clinics Supported / Sexual Wellness / Men's Sexual Health
Many men won't raise this with their primary care physician. They'll drive past three clinics to find one that handles it privately and competently. That is the business model.
Book a Strategy CallNo medical background is required to own the business. An independent, state-licensed Medical Director directs all clinical care.
Research suggests 30 million to 50 million U.S. men have ED (NIDDK), and searches for “ED treatment” run 10,000 to 100,000 a month (Google Keyword Planner).
The pills are not the business. Sildenafil and tadalafil went generic and collapsed in price. A cash-pay clinic competes instead in procedures, protocols, diagnostics and ongoing management, a considerably less crowded lane.
Our health and wellness clinic launch program takes you from market review to opening day, with no franchise fees or royalties.
Demand is not the constraint here. The constraint is building a practice men actually trust enough to walk into, and then to keep coming back to.
Google Keyword Planner, U.S., Sep 2025 to Aug 2026, in the ranges Google reports. “Erectile dysfunction clinic” and “shockwave therapy for ED” return no figure. Local demand varies by market.
How clinics in this category are commonly structured: a business model, not clinical outcomes, which are for your Medical Director and the evidence to determine.
In-office device protocols, typically sold as multi-session packages. Device selection and its cleared indications are a Medical Director decision.
Platelet-rich plasma drawn and returned to the same patient in one visit, offered under generic procedure names.
A common pairing: many men who present here are candidates for hormone evaluation.
Prescribing, titration and follow-up under physician oversight, with remote visits that support discretion, within each state's prescribing rules.
Bloodwork, hormone panels, and cardiovascular screening: sound medicine and the foundation of a defensible record.
PT-141 is an FDA-approved finished product (approved for women only, so off-label in men at the Medical Director's discretion). Most compounds patients read about, including BPC-157 and CJC-1295, are not on the 503A Bulks List.
This category attracts aggressive marketing, and the Federal Trade Commission polices health claims in advertising. The trap is that most of it is unforced. A device manufacturer hands you marketing materials, you run them as written, and your clinic now has to defend a claim about a device whose cleared indications may not cover it.
The second trap is advertising. Meta and Google both restrict this category, and operators who plan around paid social find the problem after they have signed a lease.
Ask any consultant selling you this clinic model what happens when your ad account gets banned in month two. If they do not have an answer, they have never actually launched one.
Every claim on your site, in your ads and in your consult scripts must be one your clinic can stand behind. ACG builds the messaging framework and plans a search-first strategy, since paid platforms restrict this category. Marketing execution is a separate engagement.
Shockwave therapy is not yet FDA-approved to treat ED, and a manufacturer's brochure is a sales document, not a clearance. ACG helps you confirm what each device is authorized to be marketed for before you build a service line on it.
Several branded protocol names here are registered trademarks that require training and a license. ACG reviews your service naming so you offer comparable procedures under generic descriptions.
Rules for the physician relationship, the first visit and remote follow-up differ by state. ACG maps them for your market before you commit to a model.
Structured intake, informed consent and clean records protect the practice if a claim is ever questioned. A licensed physician approves protocols and products before the first patient.
Protocols here run as multi-visit programs, and the natural pairing with hormone care means one patient often supports two service lines. ACG plans each step with you, from market analysis to opening day.
Cash-Pay
Rarely insurance covered, which means no reimbursement cycles and no payer margin erosion.
Required
An independent, state-licensed Medical Director directs all clinical care. You own and operate the business.
Launched
By our team, with 30+ years of combined experience. We help founders open in all 50 states.
Launch Window
From keys received, market and regulatory conditions permitting.
Straight answers on ownership, advertising, devices and trademarks, including the uncomfortable ones. Anything else, ask on the strategy call.
View All FAQs
Your market has these patients. Does it have the clinic? Talk with Grayson Miller about local demand, the claims and advertising picture, and what opening takes. No pitch. No obligation.
ACG is a consulting and advisory firm, not a medical practice; an independent, state-licensed Medical Director directs all clinical care. Results are not guarantees of income. Individual outcomes vary. The 60-day target begins from clinic keys received, market and regulatory conditions permitting.
Knowing the rules is the foundation of every clinic we help launch.
You own and run the business. An independent, state-licensed Medical Director makes every clinical, prescribing and treatment decision, structured for your state's Corporate Practice of Medicine laws. We connect you to a vetted network; you retain your own provider.
PRP, peptides, GLP-1 medications and cellular products each carry federal and state rules, and not every product or use is FDA-approved. Exosomes for therapeutic use are not FDA-approved at all, and we steer you away from them. Your menu and marketing are built to hold up to FDA, FTC and state medical board scrutiny.
We show real ranges and never promise an income or a clinical outcome. What you earn depends on your market, your capital and your execution.
Altos Consulting Group is a business consulting and advisory firm, not a medical practice, and does not provide, prescribe or sell any drug, biologic, device or therapy. The FDA has stated there are currently no FDA-approved exosome products for the treatment of any disease; clinic owners are responsible for the compliance of every product, therapy and claim. See the full regulatory notice below.